Not applicableUnknownNCT04651933What this trial is testingA Training Set for the HRD Model in EOCWho this might be right forEpithelial Ovarian CancerBRCA MutationLoss of Heterozygosity+3 more Lei Li 200
Early research (Phase 1)Active Not RecruitingNCT04673448What this trial is testingNiraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8BRCA-Associated Malignant Neoplasm+24 more University of Washington 18
Testing effectiveness (Phase 2)Study completedNCT02983799What this trial is testingOlaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusWho this might be right forRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity AstraZeneca 272
Large-scale testing (Phase 3)Study completedNCT02282020What this trial is testingOlaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsWho this might be right forRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity AstraZeneca 266
Early research (Phase 1)Study completedNCT04672460What this trial is testingA Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsSolid TumorsOvarian Cancer+5 more Pfizer 73
Not applicableStudy completedNCT05775549What this trial is testingCharacterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian CancerWho this might be right forAdvanced Ovarian Cancer AstraZeneca 24
Not applicableActive Not RecruitingNCT06497270What this trial is testingA 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY TrialWho this might be right forBRCA MutationEstrogen DeficiencySurgical Menopause+3 more Fondazione Policlinico Universitario Agostino Gemelli IRCCS 3
Large-scale testing (Phase 3)Active Not RecruitingNCT03740165What this trial is testingStudy of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Who this might be right forOvarian CancerFallopian Tube CancerPeritoneal Neoplasms Merck Sharp & Dohme LLC 1,367
Early research (Phase 1)Not Yet RecruitingNCT07088588What this trial is testingStudy of SYN608 for the Treatment of Advanced or Metastatic Solid TumorsWho this might be right forAdvanced Solid CancerMetastatic Solid TumorOvarian Cancer+3 more Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 105
Early research (Phase 1)Looking for participantsNCT06666270What this trial is testingStudy of SYN818 for the Treatment of Advanced or Metastatic Solid TumorsWho this might be right forAdvanced Solid CancerMetastatic Solid TumorOvarian Cancer+4 more Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 30
Not applicableActive Not RecruitingNCT01608074What this trial is testingRadical Fimbriectomy for Young BRCA Mutation CarriersWho this might be right forBRCA1 MutationBRCA2 MutationHereditary Breast and Ovarian Cancer Centre Oscar Lambret 123
Post-approval studies (Phase 4)Study completedNCT02476968What this trial is testingTo Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerWho this might be right forBRCA or HRR+ Mutated Ovarian Cancer Patients AstraZeneca 181
Not applicableActive Not RecruitingNCT04009148What this trial is testingCascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer SyndromeWho this might be right forBRCA-Mutated Ovarian CarcinomaBRIP1 Gene MutationMSH2 A636P+5 more NYU Langone Health 118
Large-scale testing (Phase 3)UnknownNCT03162276What this trial is testingTrial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation CarriersWho this might be right forHereditary Breast and Ovarian Cancer Syndrome Sheba Medical Center 118
Large-scale testing (Phase 3)Study completedNCT03402841What this trial is testingMulticentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer PatientsWho this might be right forNon-Germline BRCA Mutated Ovarian Cancer AstraZeneca 279
Not applicableUnknownNCT05409222What this trial is testingStudy of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)Who this might be right forHereditary Breast and Ovarian Cancer Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 45
Testing effectiveness (Phase 2)Study completedNCT00664781What this trial is testingRucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian CancerWho this might be right forbrca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer+1 more Cancer Research UK 78
Large-scale testing (Phase 3)Active Not RecruitingNCT01874353What this trial is testingOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyWho this might be right forPlatinum SensitiveBRCA MutatedRelapsed Ovarian Cancer+1 more AstraZeneca 327
Not applicableActive Not RecruitingNCT01907789What this trial is testingProphylactic Salpingectomy With Delayed OophorectomyWho this might be right forOvarian Carcinoma M.D. Anderson Cancer Center 80
Not applicableStudy completedNCT04532645What this trial is testingOlaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKWho this might be right forOvary Cancer AstraZeneca 342